Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled therapy aims to cut lung Tumors' sugar supply

NCT ID NCT07631299

Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether an inhaled drug called AER101 can reduce glycolysis—the process cancer cells use to break down sugar for energy—in early-stage non-small cell lung cancer. Participants inhale the drug three times daily for two weeks before their scheduled surgery. The goal is to see if the drug can shrink or weaken the tumor by cutting its fuel supply.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AER101
What this could lead to
If it works, this could point toward a new way to treat early-stage lung cancer by starving tumor cells of energy before surgery.
What could go wrong
This is a very small early-phase study with only 5 participants, so results may not apply widely. The drug may not reduce glycolysis enough to affect the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Agree to sign consent and follow study requirements * Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma * Primary patients prior to resection * Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to) * Baseline PET/CT imaging performed at Stephenson Cancer Center available and performed within previous 30 days Exclusion Criteria: * Recurrent tumor(s) * Nodal or metastatic tumor (multiple lung tumors are acceptable) * Pregnant patients * Patients unable to provide informed consent * Prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer stage I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer stage I Non-small cell lung cancer stage II

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • OU Medical Center Hospital

    Oklahoma City, Oklahoma, 73106, United States

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.